Recently, the emergence of solvent front mutations and gatekeeper mutations in RET-positive NSCLC patients has been reported as the primary cause for the development of acquired resistance against the targeted kinase inhibitors [9]. This evidence concerns the gene RET and non-small cell lung carcinoma.